Two vaccines against the deadly Bundibugyo Ebola strain gripping the Democratic Republic of Congo are set to enter trials in the outbreak's epicentre next week, the World Health Organization announced on Tuesday.
"We expect two candidate vaccines developed specifically for Bundibugyo virus to begin testing as early as next week," World Health Organization (WHO) chief Tedros Adhanom Ghebreyesus told a press conference at the United Nations health agency's headquarters in Geneva on Tuesday.
The so-called Tumaini trial in the Democratic Republic of Congo (DRC) will test the safety, efficacy and ability to trigger an immune response.
The trial uses the ring vaccination method of immunising contacts deemed to be at high risk of infection.
Ervebo, a vaccine already approved for use against the more common Zaire strain of Ebola, kicked off the Tumaini trial on 23 October, at the full-scale Phase 3 level, to determine if it also offers any protection against Bundibugyo.
There are currently no vaccines or treatments for the less common Bundibugyo species of Ebola, which is responsible for the outbreak declared in May that triggered an international public health emergency.
Health agencies have confirmed that the Ebola outbreak in eastern DRC remains out of control as the epidemic reached the six-month mark, with case numbers and deaths still rising at a record pace.
A total of 5,568 deaths out of 11,376 cases have been confirmed in what is the central African country's worst-ever Ebola outbreak, according to the WHO.
Resource shortages, instability in the country and poor coordination have hampered efforts to contain the outbreak, which is the second-largest on record globally.
DRC Ebola outbreak still 'out of control' six months on, Africa CDC warns
The two Bundibugyo-specific candidate vaccines on trial have both already passed through Phase 1 clinical trials.
One is a ChAdOx1 adenoviral vector jab developed by the University of Oxford.
The other, mRNA-1469, was developed by the United States-based Moderna group using technology made famous during the Covid-19 pandemic.
Meg Doherty, head of the WHO's science for health department, said Phase 2 clinical trials with the candidate vaccines are scheduled to begin on 26 or 27 November in Bunia, the capital of the DRC's northeastern Ituri province which is at the epicentre of the outbreak.
To complete the process, please follow the instructions in the email we just sent you.
There was a problem processing your submission. Please try again later.
If the safety and immune response data from the Phase 2 trial pass the next stage of review, the candidate jabs can move forward to a full-scale Phase 3 trial.
Doherty said that more than 140 people were enrolled in the Tumaini trial, with thousands of contacts ultimately expected to sign up.
The trial will also eventually expand beyond the current single site in Bunia.
Ebola vaccine trials 'reason for hope' in DR Congo and beyond
Ebola, which spreads through contact with bodily fluids and causes a haemorrhagic fever, has killed more than 15,000 people in Africa over the past 50 years.
Tedros said 400 to 500 new cases were still being reported every week, with two-thirds of confirmed deaths still taking place outside Ebola treatment centres.
"Children are paying a terrible price. They account for more than a quarter of confirmed cases and one third of deaths," he added.
Read or Listen to this story on the RFI website.
AllAfrica publishes around 600 reports a day from more than 100 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.
Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.
AllAfrica is a voice of, by and about Africa - aggregating, producing and distributing 600 news and information items daily from over 100 African news organizations and our own reporters to an African and global public. We operate from Cape Town, Dakar, Abuja, Johannesburg, Nairobi and Washington DC.
To complete the process, please follow the instructions in the email we just sent you.
There was a problem processing your submission. Please try again later.